Olaparib Improves Median Time Without Disease Progression in BRCAm Ovarian Cancer

September 18, 2020 3:00 pm

Olaparib (Lynparza®; AstraZeneca/Merck & Co.*) has demonstrated a long-term progression-free survival (PFS) benefit versus placebo as a 1st-line maintenance treatment in patients with newly diagnosed, advanced BRCA-mutated (BRCAm) ovarian cancer who had a complete or partial response … Read more

Phase I Data of XMT-1536 Supports Continued Development in Ovarian Cancer

September 17, 2020 1:00 pm

Updated interim safety, tolerability, and efficacy data for the ovarian cancer cohort of the ongoing expansion portion of the Phase I study evaluating XMT-1536 show a 34% objective response rate (ORR) and 79% disease control rate, including two complete responses. … Read more

PARP Inhibitors Deemed Too Costly For Across-the-Board Frontline Maintenance in Ovarian Cancer

September 11, 2020 8:00 pm

By Leah Lawrence

A new study estimated that a PARP inhibitor-for-all approach to treating advanced-stage ovarian cancer would be associated with high costs compared with biomarker-directed use of PARP inhibitors.1 Study researchers recommended that maintenance treatment with PARP inhibitors … Read more

Patient-Reported Outcomes for Rucaparib as a Maintenance Therapy in Recurrent Ovarian Cancer

September 3, 2020 5:00 pm

By Susan Moench, PhD, PA-C

Results of an exploratory analysis showed longer quality-adjusted progression-free survival (QA-PFS) and quality-adjusted time without symptoms or toxicity (Q-TWiST) in women with recurrent ovarian cancer treated with maintenance use of the poly(ADP-ribose) polymerase (PARP) inhibitor, … Read more

ASCO Releases New Guidelines on PARP Inhibitor Use for Management of Ovarian Cancer

September 1, 2020 2:00 pm

By Hannah Slater

The recommendations were based on a review of 17 clinical trials, FDA approvals, and consensus where evidence was lacking.

The American Society for Clinical Oncology (ASCO) published new guidelines on the use of PARP inhibitors in the … Read more

Research Discovery May Offer New Treatment Options for People Diagnosed With Rare Form of Ovarian Cancer

August 26, 2020 8:00 am

A recent finding by researchers at UBC’s faculty of medicine and the BC Cancer Research Institute (BCCRI) may offer a new treatment possibility for people diagnosed with a rare and aggressive form of ovarian cancer.

Small cell carcinoma of the … Read more

HIPEC With Cytoreductive Surgery Effective in Ovarian Cancer

August 25, 2020 5:00 pm

By Sarah Williams

For patients with stage III epithelial ovarian cancer, adding hyperthermic intraperitoneal chemotherapy (HIPEC) to primary cytoreductive surgery (PCS) increases survival compared with PCS alone, according to results of a retrospective study now published in JAMA Network OpenRead more

Tumor Gene Test Could Help to Predict Ovarian Cancer Prognosis

August 17, 2020 6:00 pm

A global team of medical researchers led by UNSW have developed a test that could help to predict survival for women diagnosed with ovarian cancer, and pave the way towards personalised treatment.

A tumour test could help to identify ovarian … Read more

Study Finds Patients With Rare Ovarian Cancer Develop Chemoresistance

August 7, 2020 5:00 pm

By Christina Bennett, MS

Patients with LGSC also had a significantly lower partial response rate with neoadjuvant therapy compared with patients with HGSC.

Patients with low-grade serous carcinoma of the ovary or peritoneum (LGSC) developed chemoresistance to neoadjuvant platinum-based therapy,

Read more

Be The Difference Foundation Announces Collaboration With Mary Crowley Cancer Research and The Clearity Foundation to Increase Support For Clinical Trial Participants

July 31, 2020 11:00 am

New “Caring For Her” program facilitates access to clinical trials and psychosocial support services for women with ovarian cancer.

Be The Difference Foundation today announced the launch of its “Caring For Her” program in partnership with Mary Crowley Cancer Research

Read more

Chemotherapy, Surgery for Gynecologic Cancer Not Linked to Higher COVID-19 Mortality Risk

July 30, 2020 3:00 pm

Women who underwent chemotherapy or surgery for gynecologic cancer and also had COVID-19 infection did not appear at significantly increased risk for death due to the novel coronavirus, according to study findings published in Cancer.

However, recent immunotherapy use … Read more

Survival and Clinical Outcomes of Patients with Ovarian Cancer Who Were Treated on Phase 1 Clinical Trials

July 24, 2020 3:00 pm

Corr BR, Moroney M, Sheeder J, et al

Given that ovarian cancer patients enrolled on phase 1 trials usually have platinum resistant and heavily pretreated disease, with a poor prognosis, researchers undertook this retrospective single-institution series with 132 patients to … Read more

Study: L-Grb2 Has Therapeutic Efficacy in Preclinical Models of Ovarian and Uterine Cancer

July 23, 2020 3:00 pm

The cover for issue 29 of Oncotarget features, “In vivo effects of treatment with L-Grb2 in combination with anti-angiogenic therapy in an ovarian tumor model,” by Lara, et al. which reported that adaptor proteins such as growth factor … Read more

Study Suggests QoL Assessments Do Not Support First-Line Combination Chemotherapy With Weekly Paclitaxel for Epithelial Ovarian Cancer

July 21, 2020 6:00 pm

By Susan Moench, PhD, PA-C

Results of quality of life (QoL) assessments from the randomized, phase 3 ICON8 study evaluating once-weekly vs thrice-weekly administration of paclitaxel in combination with carboplatin as first-line chemotherapy in patients with epithelial ovarian cancer do … Read more

Surgical Removal of Fallopian Tubes to Prevent Ovarian Cancer Rapidly Rising, More Research Needed to Support Its Continued Use

July 13, 2020 6:00 pm

Ten percent of women who received a hysterectomy and salpingectomy, or removal of the fallopian tubes, during the study period had a family history of breast or ovarian cancer.

By Ryan McDonald

Despite limited data to support its use, the … Read more

Study: The Immune Effects of Seclidemstat in Aggressive Ovarian Cancer Striking Young Women

July 13, 2020 3:00 pm

A drug known as SP-2577 could help enable the body’s own immune system to attack ovarian cancer, according to a study led by the Translational Genomics Research Institute (TGen), an affiliate of City of Hope.

Published today in the scientific … Read more

WEE1 Kinase Inhibitor Improved PFS in TP53-Mutated Ovarian Cancer

July 8, 2020 5:00 am

Preclinical studies of adavosertib indicated that the drug increased sensitization of TP53-mutated cells to chemotherapy.

By Leah Lawrence

Adavosertib, a WEE1 kinase inhibitor, plus carboplatin and paclitaxel improved progression-free survival (PFS) in women with TP53-mutated, platinum-sensitive ovarian cancer compared … Read more

This MicroRNA Might Help Detect, Treat Ovarian Cancer

June 26, 2020 6:00 pm

In cell and mouse models, miR-181a showed promise as a biomarker for early stage ovarian cancer and may help make immunotherapy treatment more effective.

By Ian Demsky

A microRNA that is normally involved in immune cell differentiation helps to initiate

Read more

Neoadjuvant Chemotherapy Increases Immunogenicity of High-Grade Serous Ovarian Cancer

June 23, 2020 9:00 am

By Susan Moench, PhD, PA-C

High-grade serous ovarian cancer (HGSOC) is characterized by a high level of intrinsic heterogeneity in the tumor-immune microenvironment that is modified by chemotherapy, according to findings published in Nature Genetics.

HGSOC, a common and … Read more

Treatment with Lipophilic Statins Shows Lower Mortality Rate for Patients with Epithelial Ovarian Cancer

June 22, 2020 6:00 pm

A study presented at the AACR Virtual Annual Meeting II showed a significant decrease in mortality rate for patients with epithelial ovarian cancer when treated with lipophilic statins, supporting the further evaluation of statins to treat ovarian cancer in randomized Read more